These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 23645565)

  • 41. Clinicopathologic characterisation of myeloid neoplasms with concurrent spliceosome mutations and myeloproliferative-neoplasm-associated mutations.
    Liu YC; Illar GM; Bailey NG
    J Clin Pathol; 2020 Nov; 73(11):728-736. PubMed ID: 32217616
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genetics of myelodysplastic syndromes: new insights.
    Graubert T; Walter MJ
    Hematology Am Soc Hematol Educ Program; 2011; 2011():543-9. PubMed ID: 22160087
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical applications of epigenetic markers and epigenetic profiling in myeloid malignancies.
    McDevitt MA
    Semin Oncol; 2012 Feb; 39(1):109-22. PubMed ID: 22289497
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes.
    Hamilton BK; Rybicki L; Hirsch C; Przychodzen B; Nazha A; Gerds AT; Hanna R; Kalaycio M; Sekeres MA; Sobecks R; de Lima M; Majhail NS; Maciejewski J
    Bone Marrow Transplant; 2019 Aug; 54(8):1281-1286. PubMed ID: 30655603
    [TBL] [Abstract][Full Text] [Related]  

  • 45. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
    Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
    Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A genetic development route analysis on MDS subset carrying initial epigenetic gene mutations.
    Li X; Xu F; Wu LY; Zhao YS; Guo J; He Q; Zhang Z; Chang CK; Wu D
    Sci Rep; 2020 Jan; 10(1):826. PubMed ID: 31964915
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.
    Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Fu B; Tang G; Goswami M; Singh R; Kanagal-Shamanna R; Pierce SA; Young KH; Kantarjian HM; Medeiros LJ; Luthra R; Wang SA
    Leuk Res; 2015 Mar; 39(3):348-54. PubMed ID: 25573287
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Recurrent DNMT3A R882 mutations in Chinese patients with acute myeloid leukemia and myelodysplastic syndrome.
    Lin J; Yao DM; Qian J; Chen Q; Qian W; Li Y; Yang J; Wang CZ; Chai HY; Qian Z; Xiao GF; Xu WR
    PLoS One; 2011; 6(10):e26906. PubMed ID: 22066015
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes.
    Damm F; Kosmider O; Gelsi-Boyer V; Renneville A; Carbuccia N; Hidalgo-Curtis C; Della Valle V; Couronné L; Scourzic L; Chesnais V; Guerci-Bresler A; Slama B; Beyne-Rauzy O; Schmidt-Tanguy A; Stamatoullas-Bastard A; Dreyfus F; Prébet T; de Botton S; Vey N; Morgan MA; Cross NC; Preudhomme C; Birnbaum D; Bernard OA; Fontenay M;
    Blood; 2012 Apr; 119(14):3211-8. PubMed ID: 22343920
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition.
    Giudice V; Serio B; Errichiello S; Ferrara I; Galdiero A; Bertolini A; Visconti R; De Novellis D; Guariglia R; Luponio S; Morini D; Della Corte AM; Sessa AM; Verdesca F; Langella M; Izzo B; Selleri C
    Eur J Haematol; 2023 Nov; 111(5):729-741. PubMed ID: 37501402
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of therapy-related myelodysplastic syndrome with ring sideroblasts and de novo myelodysplastic syndrome with ring sideroblasts.
    Chen Z; Wang SA; Goswami M; Tang G; Routbort MJ; Patel KP; Luthra R; Medeiros LJ; Ok CY
    Leuk Res; 2019 Nov; 86():106227. PubMed ID: 31557598
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome.
    Xu F; Liu L; Chang CK; He Q; Wu LY; Zhang Z; Shi WH; Guo J; Zhu Y; Zhao YS; Gu SC; Fei CM; Li X
    Oncotarget; 2016 Feb; 7(7):8119-30. PubMed ID: 26812882
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Genetic alterations in Thai adult patients with acute myeloid leukemia and myelodysplastic syndrome-excess blasts detected by next-generation sequencing technique.
    Owattanapanich W; Herzig J; Jahn N; Panina E; Ruchutrakool T; Kungwankiattichai S; Issaragrisil S; Döhner H; Döhner K
    Ann Hematol; 2021 Aug; 100(8):1983-1993. PubMed ID: 33839881
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Research progress on mechanism of MDS transformation into AML].
    Wang LL; Gao C; Chen BA
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Feb; 19(1):254-9. PubMed ID: 21362264
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia.
    Gonzalez-Lugo JD; Chakraborty S; Verma A; Shastri A
    Semin Hematol; 2021 Jan; 58(1):56-65. PubMed ID: 33509444
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Genetic variants involved in oxidative stress, base excision repair, DNA methylation, and folate metabolism pathways influence myeloid neoplasias susceptibility and prognosis.
    Gonçalves AC; Alves R; Baldeiras I; Cortesão E; Carda JP; Branco CC; Oliveiros B; Loureiro L; Pereira A; Nascimento Costa JM; Sarmento-Ribeiro AB; Mota-Vieira L
    Mol Carcinog; 2017 Jan; 56(1):130-148. PubMed ID: 26950655
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The role of mutations in epigenetic regulators in myeloid malignancies.
    Shih AH; Abdel-Wahab O; Patel JP; Levine RL
    Nat Rev Cancer; 2012 Sep; 12(9):599-612. PubMed ID: 22898539
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome.
    Mian SA; Smith AE; Kulasekararaj AG; Kizilors A; Mohamedali AM; Lea NC; Mitsopoulos K; Ford K; Nasser E; Seidl T; Mufti GJ
    Haematologica; 2013 Jul; 98(7):1058-66. PubMed ID: 23300180
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genetics of progression from MDS to secondary leukemia.
    Menssen AJ; Walter MJ
    Blood; 2020 Jul; 136(1):50-60. PubMed ID: 32430504
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.
    Zhang L; McGraw KL; Sallman DA; List AF
    Leuk Lymphoma; 2017 Aug; 58(8):1777-1790. PubMed ID: 27967292
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.